Please login to the form below

Not currently logged in
Email:
Password:

Gamida Cell strengthens leadership team

Appoints Josh Hamermesh and Paul Nee

Josh HamermeshCellular and immune therapeutics group Gamida Cell has appointed a new chief business officer in the form of Josh Hamermesh.

Hamermesh (pictured right), who joins from Locust Walk Partners where he served as senior vice president, will lead the business operations and corporate development strategies for the company.

He has also served as vice president, business and corporate development at Infinity Pharmaceuticals, where he was responsible for the company’s in-licensing, out-licensing and alliance management activities.

Paul NeeAlongside Hamermesh, Gamida Cell has appointed Paul Nee (pictured left) as its vice president of marketing.

Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.

Julian Adams, chairman and chief executive officer of Gamida Cell, said: “We are pleased to welcome Josh and Paul to the Gamida Cell leadership team.

“Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic diseases.”

4th May 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Cutting through the noise
AstraZeneca looks to lead an R&D revolution as the company invests in CRISPR and functional genomics drug discovery...
International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...

Infographics